Viking Therapeutics (VKTX) Payables: 2014-2025
Historic Payables for Viking Therapeutics (VKTX) over the last 11 years, with Sep 2025 value amounting to $4.4 million.
- Viking Therapeutics' Payables rose 1637.40% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.4 million, marking a year-over-year increase of 13.87%. This contributed to the annual value of $9.8 million for FY2024, which is 30.63% up from last year.
- Viking Therapeutics' Payables amounted to $4.4 million in Q3 2025, which was down 19.68% from $5.5 million recorded in Q2 2025.
- In the past 5 years, Viking Therapeutics' Payables registered a high of $11.1 million during Q2 2024, and its lowest value of $254,000 during Q3 2024.
- For the 3-year period, Viking Therapeutics' Payables averaged around $6.1 million, with its median value being $5.6 million (2023).
- Per our database at Business Quant, Viking Therapeutics' Payables tumbled by 95.55% in 2024 and then skyrocketed by 1,637.40% in 2025.
- Over the past 5 years, Viking Therapeutics' Payables (Quarterly) stood at $1.4 million in 2021, then soared by 490.65% to $8.5 million in 2022, then dropped by 11.92% to $7.5 million in 2023, then surged by 30.63% to $9.8 million in 2024, then surged by 1,637.40% to $4.4 million in 2025.
- Its Payables stands at $4.4 million for Q3 2025, versus $5.5 million for Q2 2025 and $7.7 million for Q1 2025.